Ultragenyx/Mereo: Ahead of the imminent ORBIT and COSMIC Osteogenesis Imperfecta setrusumab phase III expected within December/January, our comprehensive report reveals phase II improvements in bone density and fracture reduction are unlikely attributable solely to the natural improvement in osteogenesis with age but are likely due to setrusumab, boding well for both phase III trails